From: Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection
Cohorts (N)
ORRa
N (%)
Any Grade irAEs
Grade ≥ 3 irAEs
HIV (21)
2 CR/3 PR (28)
5 (24)
3 (14)
HBV/HCV (34)
6 PR (18)
15 (44)
10 (29)b